Correction to: Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

被引：0
|
作者：
Fabian Sierra Morales
Igor J. Koralnik
Shiva Gautam
Soleil Samaan
Jacob A. Sloane
机构：
[1] Harvard Medical School,Division of Neuro
[2] Harvard Medical School,Immunology, Department of Neurology, Beth Israel Deaconess Medical Center, Multiple Sclerosis Center
[3] Harvard Medical School,Division of Biostatistics, Department of Medicine, Beth Israel Deaconess Medical Center
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Unfortunately, the given name and family name of first author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as “Morales FS” in Pubmed. The correct given name is Fabian and family name is Sierra Morales. Auhtor name should be abbreviated as Sierra Morales F.
引用
收藏
页码：132 / 132
相关论文
共 50 条
  • [1] Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate
    Morales, Fabian Sierra
    Koralnik, Igor J.
    Gautam, Shiva
    Samaan, Soleil
    Sloane, Jacob A.
    JOURNAL OF NEUROLOGY, 2020, 267 (01) : 125 - 131
  • [2] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [3] Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis: Effects of Dose Reduction on Lymphopenia
    Wong, Ka-Ho
    Marini, Erica
    Clardy, Stacey
    DeWitt, L.
    Klein, Julia
    Soldan, M. Paz
    Rose, John
    NEUROLOGY, 2017, 88
  • [4] Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis
    Ravn, Julie
    Jensen, Henrik Boye
    Kant, Matthias
    Andersen, Preben Borring
    Gora, Monika Katarzyna
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [5] Risk factors for Development of Lymphopenia in Dimethyl Fumarate-treated Patients with Multiple Sclerosis
    Bloch, Caroline Holst
    Sejbaek, Tobias
    Kant, Matthias
    Blaabjerg, Morten
    Jensen, Henrik Boye
    Andersen, Preben
    Petersen, Annett
    Gora, Monika
    NEUROLOGY, 2019, 92 (15)
  • [6] Persistent lymphopenia after routine clinical use of dimethyl fumarate for relapsing remitting multiple sclerosis
    MacDougall, N. J.
    Gallagher, P.
    Murdoch, S.
    Murray, L.
    Webb, S.
    Overell, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 300 - 300
  • [7] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
  • [8] Predictive factors of lymphopenia in a young cohort of Multiple Sclerosis patients treated with Dimethyl Fumarate
    Krupka, Danna
    Ferreira, Vitor Mendes
    Correia, Ana Sofia
    Teixeira, Manuel Salavisa
    Serrazina, Filipa
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 971 - 971
  • [9] Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis: 24 Months Observations of the Effects of Dose Reduction on Lymphopenia
    Wong, Ka-Ho
    Marini, Erica
    Tram Nguyen
    Clardy, Stacey
    Cortez, Melissa
    DeWitt, L.
    Greenlee, John
    Klein, Julia
    Soldan, M. Paz
    Steffens, John
    Rose, John
    NEUROLOGY, 2018, 90
  • [10] Longitudinal Data on Lymphopenia in Multiple Sclerosis Patients Treated with Dimethyl Fumarate
    Romba, Meghan
    Wundes, Annette
    Von Geldern, Gloria
    NEUROLOGY, 2016, 86
12345